Trial Profile
A Phase II Clinical Trial of Nedaplatin and Amurubicin Therapy for Advanced and Recurrent Squamous Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2020
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Nedaplatin (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 07 Oct 2020 Status changed from recruiting to completed.
- 03 Apr 2012 New trial record